During the 2022-23 and 2024-25 flu seasons, the incidence of cardiorespiratory hospitalization was 2.25% in the high-dose group and 2.38% in the standard-dose group.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
Sep 16, 2010
(CIDRAP News) Observers who staked out public restrooms in four US cities found that 85% of people using the facilities washed their hands afterward, the highest level since researchers began regularly studying the behavior in 1996, according to a report released yesterday.
Sep 14, 2010
(CIDRAP News) – Japan today approved a new long-acting influenza antiviral drug, Inavir (laninamivir), made by Daiichi Sankyo Co. Ltd., marking the second new flu drug licensed there this year.
Sep 10, 2010
Sep 9, 2010
Sep 8, 2010
Sep 7, 2010
